KXAN

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to ...
Seeking Alpha

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

These results pave the way for filing an NDA for the use of PAX-101 (intravenous suramin) for the treatment of African Sleeping Sickness TARRYTOWN, NY, July 24, 2023 (GLOBE NEWSWIRE) -- via ...
Benzinga.com

Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies

Friday, PaxMedica Inc (NASDAQ:PXMD) completed the execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This ...
KTLA

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations As previously ...
Seeking Alpha

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today ...